Long-term open-label abrocitinib extension study in pediatric moderate-to-severe atopic dermatitis

Phase 3, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoint: Number of participants with treatment-emergent adverse events, serious adverse events, and adverse events leading to study discontinuation. Started Dec 2025; status: recruiting.